In the world of healthcare litigation, few cases have rattled the pharmacy benefit manager (PBM) industry as profoundly as United States ex rel. Behnke v. CVS Caremark, No. 2:2014-cv-00824 (E.D. Pa. 2025).
What began in 2014 as a whistleblower’s suspicion inside a corporate office culminated in 2025 with a staggering $290 million judgment. This case pulled back the curtain on “spread pricing” and the opaque financial maneuvers that critics argue drive up the cost of prescription drugs for the American taxpayer.
Here is a deep dive into the case that has put every PBM in the country on notice.
The Genesis: A Whistleblower’s Discovery
The case was initiated by Sarah Behnke, a former head actuary for Medicare Part D at Aetna. In 2012, Behnke noticed discrepancies in how CVS Caremark—Aetna’s PBM at the time—was reporting drug costs.
As an actuary, Behnke’s job was to assess risk and value. She suspected that Caremark was engaging in a sophisticated “double-dipping” scheme: charging Medicare (through Aetna) one price for generic drugs while paying pharmacies like Walgreens and Rite Aid a significantly lower amount, and pocketing the difference—all while failing to report these “savings” to the government.
The Mechanism of Fraud: Spread Pricing and GERs
To understand the legal battle, one must understand the two ways PBMs set prices:
- MAC (Maximum Allowable Cost): The individual price set for a specific drug at the point of sale.
- GER (Generic Effective Rate): A “guaranteed average” price a PBM agrees to pay a pharmacy across all generic drug sales over a year.
The court found that Caremark was reporting the higher MAC prices to the Centers for Medicare & Medicaid Services (CMS) as the “actual” cost of the drugs. However, Caremark was actually paying the pharmacies the lower GER prices.
Under federal law, PBMs are required to report “pass-through” prices—meaning the government should benefit from the lower rates negotiated with pharmacies. By hiding the lower GER rates, Caremark allegedly caused the government to overpay hundreds of millions of dollars in subsidies.
The Decade-Long Legal War
The lawsuit was filed in 2014 under the False Claims Act (FCA), which allows private citizens (relators) to sue on behalf of the government. Interestingly, the U.S. government declined to intervene in 2018, leaving Behnke to fight the case with her own legal team for another seven years.
Caremark’s primary defense was a concept called “materiality.” They argued that even if their reporting was technically inaccurate, CMS knew about these pricing structures and paid the claims anyway, meaning the “error” wasn’t material to the government’s decision to pay.
Chief Judge Mitchell S. Goldberg of the Eastern District of Pennsylvania disagreed. In his 105-page opinion in June 2025, he ruled that the reporting was not just an “innocent mistake” but a “financially motivated” fraud.
The Verdict: From $95 Million to $290 Million
In June 2025, the court initially found Caremark liable for $95 million in actual damages. However, under the False Claims Act, damages are subject to trebling (tripling) to act as a deterrent.
By August 2025, Judge Goldberg finalized the judgment:
- Trebled Damages: $285,000,000
- Civil Penalties: $4,873,500 (based on 513 false reports)
- Total Judgment: $289,873,500
The judge noted that the severity of the penalty was justified by Caremark’s “serious” misconduct and the fact that the PBM knowingly caused insurers to misrepresent costs to Medicare.
Why This Case Matters (The Ripple Effect)
The Behnke decision is more than just a massive fine; it is a landmark precedent that reshapes the legal landscape for PBMs and plan sponsors.
The Death of Opacity
For years, PBMs have guarded their pricing contracts as trade secrets. This case proves that the “black box” of drug pricing can be cracked open in court. It signals to other PBMs that their internal “spreads” are now subject to federal transparency standards.
A Warning to Plan Sponsors (ERISA Implications)
While Behnke was an FCA case involving Medicare, it has sparked a wave of private litigation. In 2025, companies like JPMorgan Chase, Johnson & Johnson, and Wells Fargo faced class-action lawsuits from their own employees.
The theory? If a PBM is overcharging the plan, the employer (as a fiduciary under ERISA) has a legal duty to catch it. The Behnke evidence is now being used by plaintiffs to argue that employers are “asleep at the wheel” when it comes to overseeing their PBM contracts.
Regulatory Reform
The ruling has fueled legislative fire in Washington. Since the verdict, there has been a renewed push to ban “spread pricing” entirely in federal programs. CMS has already begun implementing stricter “Direct and Indirect Remuneration” (DIR) reporting rules to ensure PBMs cannot hide these discounts.
What Makes Behnke v. Caremark Unique?
While healthcare fraud cases are common, several extraordinary factors set Behnke apart, making it a study in persistence and technical precision.
The “Lone Wolf” Victory
In roughly 80% of successful False Claims Act cases, the Department of Justice (DOJ) intervenes to take over the heavy lifting. In this case, the government declined to intervene in 2018. Usually, this is the “kiss of death” for a whistleblower suit, as private relators rarely have the resources to fight a multi-billion-dollar corporation alone for a decade. Sarah Behnke’s decision to proceed “declined” and ultimately win a $290 million judgment is an extreme rarity in the legal world.
The Actuary as the Ultimate Insider
Most whistleblowers are sales reps or mid-level managers who witness a specific “kickback” or “shady deal.” Behnke was a Head Actuary. This provided her with a “bird’s-eye view” of the math. She didn’t just see one bad transaction; she understood the algorithmic manipulation of “Generic Effective Rates” (GER) across an entire book of business. The case turned on complex financial modeling that only an actuary could have reverse-engineered, making it a “math-driven” victory rather than a “smoking gun memo” victory.
Defeating the “Government Knowledge” Defense
Caremark’s strongest defense was a common one: “The government (CMS) knew we were doing this and paid us anyway, so it must not be fraud.” In many recent cases (following the Supreme Court’s Escobar ruling), this defense has worked. However, Judge Goldberg’s 105-page opinion meticulously dismantled this, ruling that “passive awareness” by a busy government agency does not equate to “active approval” of fraud. This provides a new roadmap for future whistleblowers to bypass the “but they knew!” defense used by large contractors.
Cross-Market Subsidization
The trial revealed a startling motive: the court found that Caremark used the inflated profits from Medicare (taxpayer money) to subsidize lower prices in the private commercial market. This allowed them to undercut competitors and win more corporate contracts. This “cross-market manipulation” showed that the fraud wasn’t just about greed—it was a strategic tool used to gain an unfair advantage in the broader insurance industry, a revelation that has since sparked antitrust investigations.
Final Thoughts: The Road Ahead
CVS Caremark has filed a notice of appeal to the Third Circuit, and the U.S. Chamber of Commerce has filed amicus briefs arguing that the court’s interpretation of “falsity” is too broad. The final chapter of Behnke v. Caremark may not be written for another year or two.
However, the message to the healthcare industry is clear: Transparency is no longer optional. As whistleblowers become more sophisticated and courts become less tolerant of complex pricing shells, the era of the “PBM spread” may be coming to an end.